US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Australia's deputy prime minister pledges support to Solomon Islands during visit to Honiara
NEWCASTLE, Australia (AP) — Australia’s deputy prime minister pledged support to the Solomon Islands2024-05-22- CHARLOTTE, N.C. (AP) — It took just a few days for United Methodist delegates to remove a half-centu2024-05-22
Champions League: Bayern and Dortmund could stop Mbappe's showdown with Real Madrid
Real Madrid needs fortress Bernabeu to live up to its reputation. Paris Saint-Germain could do with2024-05-22City traders fired after being caught having sex with a cleaner in the office after
It is a sex scandal that even by the sometimes debauched standards of City traders has set tongues w2024-05-22Wayne Bennett, at 74, signs a 3
BRISBANE, Australia (AP) — The 74-year-old Wayne Bennett has ended speculation about his coaching fu2024-05-22- BRIGHTON, England (AP) — Joao Pedro scored an 87th-minute winner as Brighton beat Aston Villa 1-0 in2024-05-22
atest comment